微针介导的豚鼠耳蜗内地塞米松注射的生理效应
该研究在5只Hartley豚鼠中经圆窗膜用100微米空心微针注射1.0微升10毫克/毫升地塞米松,注射前、注射后1小时和5小时测量复合动作电位(CAP)和畸变产物耳声发射(DPOAE)。结果显示注射后1小时部分频率出现CAP阈值和DPOAE变化,5小时恢复至基线,支持微针技术用于内耳疾病治疗。
要点
- 豚鼠耳蜗内微针注射地塞米松后1小时出现暂时性听力阈值变化。
- 注射后5小时CAP阈值和DPOAE恢复至基线水平。
- 结果支持微针技术用于内耳疾病治疗。
核心结论
- 经微针直接耳蜗内地塞米松注射引起暂时性听力阈值变化,5小时内恢复,支持微针技术用于内耳疾病治疗。
研究设计与样本
- 在5只Hartley豚鼠中经耳后切口及鼓室切开暴露圆窗膜,用100微米直径空心微针在1分钟内注射1.0微升10毫克/毫升地塞米松。
主要发现
- 方差分析(ANOVA)发现4个频率(4、16、36、40 kHz)的CAP阈值变化有统计学意义,以及1个频率(6 kHz)的DPOAE差异有统计学意义。
- 配对t检验显示穿孔前与注射后1小时时间点之间存在差异。
- 注射后5小时CAP听阈和DPOAE均恢复,与基线阈值无显著差异。
关键数值与推荐
- CAP听阈测量频率范围为0.5至40 kHz,DPOAE f2频率范围为1.0至32 kHz。
- 地塞米松注射浓度为10毫克/毫升,注射体积为1.0微升,注射时间为1分钟。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Oral or intratympanic corticosteroids are commonly used to treat sudden sensorineural hearing loss (SSHL), tinnitus, and Meniere disease. Direct intracochlear delivery has been proposed to overcome the variability in bioavailability and efficacy of systemic or middle ear delivery. In this study, we aim to characterize the physiologic consequences of microneedle-mediated direct intracochlear injection of dexamethasone through the round window membrane (RWM). METHODS: In Hartley guinea pigs (n = 5), a post-auricular incision followed by bullostomy was made to access the round window membrane. Using 100 μm diameter hollow microneedles, 1.0 μl of 10 mg/ml dexamethasone was injected through the RWM over 1 min. Compound action potential (CAP) and distortion product otoacoustic action emissions (DPOAE) were measured before perforation, at 1 h, and at 5 h following injection. CAP hearing thresholds were measured from 0.5 to 40 kHz, and DPOAE f2 frequencies ranged from 1.0 and 32 kHz. Repeated measures ANOVA followed by pairwise t-tests were used for statistical analysis. RESULTS: ANOVA identified significant CAP threshold shifts at four frequencies (4, 16, 36, and 40 kHz) and differences in DPOAE at 1 frequency (6 kHz). Paired t-tests revealed differences between the pre-perforation and 1 h time point. By 5 h post injection, both CAP hearing thresholds and DPOAE recover and are not significantly different from baseline thresholds. CONCLUSION: Direct intracochlear delivery of dexamethasone via microneedles results in temporary shifts in hearing thresholds that resolve by 5 hours, thus supporting microneedle technology for the treatment of inner ear disorders. LEVEL OF EVIDENCE: NA Laryngoscope, 134:388-392, 2024.
引用
- Feng SJ, Leong S, Aksit A, et al. Physiologic Effects of Microneedle-Mediated Intracochlear Dexamethasone Injection in the Guinea Pig. Laryngoscope. 2023. PMID: 37318112. doi:10.1002/lary.30811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。